Time Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective: The authors evaluated the time course of the treatment effect of Osmotic-Release Oral System methylphenidate (OROS® MPH) HCl (Concerta®, Raritan, NJ) CII in children with ADHD. Method: Data were combined from two double-blind, randomized, placebo-controlled, cross-over, analog classroom studies in children (9-12 years) with ADHD. Participants received an individualized dose of placebo or OROS® MPH on two laboratory school days. Permanent Product Math Test and Swanson, Kotkin, Agler, M-Flynn, and Pelham scores were evaluated 0.5 hr before dosing and 1, 2, 4, 10, 11, and 12.5 hr post dose. Analysis used a repeated-measures mixed model. Results: Treatment effects were present at all postdose assessment points ( p < .0001 for all comparisons, n = 139). Adverse events were similar to previous reports for OROS® MPH. Conclusion: A robust treatment effect occurred with OROS® MPH; onset was at 1 hr and persisted for at least 12.5 hr after dosing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
Faraone, S. V., & Buitelaar, J. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0054-3 · Cited by 485 · cited 1×
“…ADHD is robust, ranging from 0.79 to ≥1.0, varying by study design factors, including age range of participant, informant, length of study, dose, comparator, and other factors (Faraone & Buitelaar, 2010; Schachter, Pham, King, Langford, & Moher, 2001; Smith, Waschbusch, Willoughby, & Evans, 2000).”
InfluentialPelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M., Chronis, A. M., Forehand, G. L., Nguyen, C. A., Hoffman, M. T., et al. (2001) · Pediatrics · doi:10.1542/peds.107.6.e105 · Cited by 378 · cited 5×
“5 hr post dose, with a duration of action through 12 hr post dose (Pelham et al., 2001; Swanson et al., 2003; Swanson et al., 2004).”
BackgroundInfluentialBiederman, J., Boellner, S. W., Childress, A., Lopez, F. A., Krishnan, S., & Zhang, Y. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.015 · Cited by 360 · cited 2×
“The PERMP has been shown to be sensitive to the effects of several different ADHD treatments in a number of studies that evaluated behavior in classroom-like settings (e.g., Biederman et al., 2007; Brams et al., 2008; Faraone, Wigal, & Hodgkins, 2007; Greenhill et al., 2003).”
BackgroundMethodSwanson, J., Gupta, S., Lam, A., Shoulson, I., Lerner, M., Modi, N., Lindemulder, E., & Wigal, S. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.2.204 · Cited by 248
Swanson, J. M., Wigal, S. B., Wigal, T., Sonuga-Barke, E., Greenhill, L. L., Biederman, J., Kollins, S., Nguyen, A. S., DeCory, H. H., Hirshe Dirksen, S. J., et al. (2004) · Pediatrics · doi:10.1542/peds.113.3.e206 · Cited by 238 · cited 3×
“In the three previously published simulated school studies (Pelham et al., 2001; Swanson et al., 2003; Swanson et al., 2004), doses were determined for each child based on their previously established MPH dose (low, medium, or high).”
BackgroundInfluentialSwanson, J., Gupta, S., Guinta, D., Flynn, D., Agler, D., Lerner, M., Williams, L., Shoulson, I., & Wigal, S. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70038-x · Cited by 216
the 311 Study Group, Wigal, S. B., Kollins, S. H., Childress, A. C., & Squires, L. (2009) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-3-17 · Cited by 110
McGough, J. J., Wigal, S. B., Abikoff, H., Turnbow, J. M., Posner, K., & Moon, E. (2006) · Journal of Attention Disorders · doi:10.1177/1087054705284089 · Cited by 103
Cited by
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Storebø, O. J., Ramstad, E., Krogh, H. B., Nilausen, T. D., Skoog, M., Holmskov, M., Rosendal, S., Groth, C., Magnusson, F. L., Moreira-Maia, C. R., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009885.pub2 · Cited by 347
Does methylphenidate improve academic performance? A systematic review and meta-analysis
Kortekaas-Rijlaarsdam, A. F., Luman, M., Sonuga-Barke, E., & Oosterlaan, J. (2019) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-018-1106-3 · Cited by 99
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents
Childress, A. C., & Berry, S. A. (2012) · Drugs · doi:10.2165/11599580-000000000-00000 · Cited by 77
López, F. A., & Leroux, J. R. (2013) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-013-0106-x · Cited by 43
Metadata
- Authors
- Armstrong, R. B., Damaraju, C., Ascher, S., Schwarzman, L., O’Neill, J., & Starr, H. L.
- Venue
- Journal of Attention Disorders
- Publisher
- SAGE Publications
- Published
- 2011-11-14
- Volume
- 16
- Issue
- 8
- Pages
- 697-705
- ISSN
- 1087-0547 (ISSN-L)
- 1557-1246
- OpenAlex
- W2099872220
- Cited by
- 23
- References
- 8
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Time Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD. https://app.cochat.ai/papers/10.1177/1087054711425772
- The paper
- Armstrong, R. B., Damaraju, C., Ascher, S., Schwarzman, L., O’Neill, J., & Starr, H. L. (2012). Time Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD. Journal of Attention Disorders. https://doi.org/10.1177/1087054711425772
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.